Market Overview

Impax Labs Shares Down Sharply After FDA CRL for RYTARY NDA; Canaccord Says Buy the Dip

Related IPXL
8 Attractive U.S. Healthcare Stocks With Low PEG Ratios
Teva Beats Q3 Earnings Expectations, Updates Outlook
Middle-Market Deal Making Surges in First Three Quarters (Fox Business)

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced early Sunday the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for RYTARY™ (IPX066), an extended-release capsule formulation of carbidopa-levodopa, a potential treatment for the symptomatic treatment of Parkinson's disease currently under review in the United States.

The complete response letter indicates that the FDA requires a satisfactory re-inspection of the company's Hayward facility as a result of the warning letter issued in May 2011 before the company's NDA may be approved due to the facility's involvement in the development of RYTARY, and supportive manufacturing and distribution activities. During the assessment of the NDA, the company withdrew the Hayward site as an alternative site of commercial production at launch.

“We will work with the FDA on the appropriate next steps for the RYTARY application,” said Larry Hsu, Ph.D., president and CEO, Impax Laboratories, Inc. “We remain committed to resolving the warning letter and bringing this new treatment option to patients who are suffering from Parkinson's disease.”

A complete response letter is issued by the FDA's Center for Drug Evaluation and Research when the review cycle for a drug is complete and the application is not yet ready for approval.

Following the move lower, Canaccord Genuity's Randall Stanicky is advising clients to buy the weakness in shares of Impax. Stanicky believes Impax will soon directly address the FDA's concerns, potentially pushing shares closer to $25.

Latest Ratings for IPXL

DateFirmActionFromTo
Nov 2014Piper JaffrayDowngradesOverweightNeutral
Nov 2014Bank of AmericaMaintainsUnderperform
Oct 2014JMP SecuritiesInitiates Coverage onOutperform

View More Analyst Ratings for IPXL
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings Movers

 

Related Articles (IPXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters